Fixed-dose combination
Brimonidine and Carbachol is a fixed-dose combination of a cholinergic receptor agonist and an alpha-adrenergic agonist indicated for the treatment of presbyopia in adults. It is available as eye drops for ophthalmic use. MedsAcross supplies Brimonidine and Carbachol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
YUVEZZI™ is indicated for the treatment of presbyopia in adults. YUVEZZI is a combination of carbachol, a cholinergic agonist, and brimonidine, an alpha-adrenergic receptor agonist, indicated for the treatment of presbyopia in adults.
Source: US FDA prescribing information
The proposed mechanism of action of this fixed-dose combination of carbachol and brimonidine in presbyopia is pupillary constriction and the creation of a pinhole effect that improves near visual acuity and depth of focus. Carbachol is a cholinergic agent which produces constriction of the iris sphincter and ciliary body. Brimonidine tartrate, an alpha-adrenergic agonist, blocks contraction of the iris dilator muscle and relaxes tonic contraction of the ciliary muscle, enhancing selectivity for the pupil and increasing bioavailability of carbachol in the aqueous humor.
Source: US FDA prescribing information
Instill one drop in each eye once daily. Recommended Dosage The recommended dosage of YUVEZZI is one drop in each eye once daily. Administration Instructions Remove contact lenses prior to instillation of YUVEZZI. Wait 10 minutes after dosing before reinserting contact lenses. If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart. One single-dose vial can be used to dose both eyes. Discard the open single-dose vial and any remaining contents immediately after use.
Source: US FDA prescribing information
YUVEZZI is contraindicated in patients with known hypersensitivity to the active ingredients or to any of the excipients. Hypersensitivity.
Source: US FDA prescribing information
Blurred Vision: Advise patients not to drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous activities in poor illumination. Risk of Retinal Detachment: Rare cases of retinal tear and detachment have been reported with miotics. Individuals with preexisting retinal disease are at increased risk. Therefore, examination of the retina is advised in all patients prior to initiation of therapy. Patients should be advised to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss. Iritis: Caution is advised in patients with iritis. Potentiation of Vascular Insufficiency: Use with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in labeling: Hypersensitivity Most common adverse reactions (incidence >5%) are eye pain upon instillation, visual impairment, eye irritation upon instillation, and headache.
Source: US FDA prescribing information
Antihypertensives/cardiac glycosides may lower blood pressure. Use with CNS depressants may result in an additive or potentiating effect. Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine. Monoamine oxidase inhibitors may result in increased hypotension.
Source: US FDA prescribing information
Store at 36°F to 77°F (2°C to 25°C). Once a pouch is opened, store the single-dose vials in the foil pouch away from light until ready for use.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Brimonidine and Carbachol, sorted by availability.
| Medicine | Active ingredient | Manufacturer | Register | Availability |
|---|---|---|---|---|
| Yuvezzi 1 mg/27.5 mg per mL eye dropsOphthalmic | Brimonidine and Carbachol | Visus Therapeutics | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 28 January 2026 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Brimonidine and Carbachol and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Brimonidine and Carbachol, including Yuvezzi.
Yes. The US FDA first approved Brimonidine and Carbachol on 28 January 2026, according to Drugs@FDA.
No listed presentation of Brimonidine and Carbachol is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.